Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations.
Alessio CortelliniBiagio RicciutiVictor R VazDavide SoldatoJoao M Victor AlessiFilippo G Dall'OlioGiuseppe L BannaSethupathi MuthuramalingamSamuel ChanMargarita Majem TarruellaAida PiedraGiuseppe LambertiElisa AndriniAlfredo AddeoAlex FriedlaenderFrancesco FacchinettiTeresa GorríaLaura MezquitaDelphine HotonLacroix ValerieFrank Aboubakar NanaJames ArtingstallCharles CominsMassimo Di MaioAndrea CaglioJudith CaveHayley McKenzieThomas Newsom-DavisJoanne S EvansMarcello TiseoAntonio D'AlessioClaudia A M FulgenziBenjamin BesseMark M AwadDavid James PinatoPublished in: Journal for immunotherapy of cancer (2022)
In contrast to what was observed in the context of chemotherapy-free ICI-based regimens, baseline BMI does not affect clinical outcomes from chemoimmunotherapy combinations in patients with advanced NSCLC.